dexrazoxane has been researched along with Acute Lymphoid Leukemia in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andelfinger, G; Caru, M; Curnier, D; Krajinovic, M; Lapointe, MO; Laverdière, C; Périé, D; Raboisson, MJ; Sinnett, D | 1 |
| Andelfinger, G; Ansari, M; Bertout, L; Drouin, S; Elbared, J; Krajinovic, M; Kutok, JL; Laverdière, C; Lipshultz, SE; Neuberg, DS; Raboisson, MJ; Rezgui, A; Sallan, SE; Silverman, LB; Sinnett, D | 1 |
| Armenian, SH; Asselin, BL; Borowitz, MJ; Camitta, BM; Chen, L; Devidas, M; Franco, VI; Hutchison, RE; Lipshultz, SE; Pullen, J; Ravindranath, Y | 1 |
| Anderson, LM; Franco, VI; Gerschenson, M; LiButti, DE; Lipshultz, SE; Miller, TL; Neuberg, DS; Sallan, SE; Silverman, LB; Stevenson, KE; Vrooman, LM | 1 |
2 trial(s) available for dexrazoxane and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Cardiotonic Agents; Cardiotoxicity; Child; Child, Preschool; Dexrazoxane; Doxorubicin; Female; Genetic Predisposition to Disease; Heart Diseases; Heterozygote; Homozygote; Humans; Infant; Male; Multidrug Resistance-Associated Proteins; Myocardial Contraction; Nitric Oxide Synthase Type III; Pharmacogenetics; Pharmacogenomic Variants; Phenotype; Polymorphism, Single Nucleotide; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protective Factors; Risk Assessment; Risk Factors; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left; Young Adult | 2016 |
Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology Grou
Topics: Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathies; Cardiotonic Agents; Cardiotoxicity; Child; Dexrazoxane; Doxorubicin; Female; Humans; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Treatment Outcome; Troponin T | 2016 |
2 other study(ies) available for dexrazoxane and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
Dexrazoxane Treatments Limits Subclinical Cardiac Dysfunction in Childhood Acute Lymphoblastic Leukemia Survivors Exposed to Doxorubicin Treatments.
Topics: Cardiotoxicity; Dexrazoxane; Doxorubicin; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Stroke Volume; Survivors; Ventricular Dysfunction, Left; Ventricular Function, Left | 2023 |
Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors.
Topics: Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cardiotonic Agents; Child; Child, Preschool; Chromatography, Thin Layer; Cross-Sectional Studies; Dexrazoxane; DNA Copy Number Variations; DNA, Mitochondrial; Doxorubicin; Electron Transport Complex I; Electron Transport Complex IV; Female; Follow-Up Studies; Humans; Infant; Leukocytes, Mononuclear; Male; Mitochondria, Heart; Oxidation-Reduction; Phosphorylation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Real-Time Polymerase Chain Reaction; Sex Factors; Survivors | 2016 |